Glaukos (GKOS) has drawn investor attention after recent trading, with the stock last closing at $127.53. The move comes as the ophthalmic therapy company continues to develop treatments across glaucoma, corneal disorders and retinal diseases.
See our latest analysis for Glaukos.
Glaukos stock has eased around 11% over the past month, even though the 90 day share price return of 23.55% and 1 year total shareholder return of 27.77% point to momentum that has been positive over a longer stretch.
If the recent move in Glaukos has you thinking about where else growth in medical and AI driven care could emerge, it may be worth scanning 40 healthcare AI stocks
With Glaukos stock easing in the short term yet showing stronger returns over longer periods, and with measures like intrinsic value estimates and analyst targets suggesting a gap to current levels, the key question is whether this is a genuine opportunity or if the market is already fully reflecting expectations for future growth.
Most Popular Narrative: 15.6% Undervalued
Glaukos is trading at $127.53, while the most followed narrative places fair value closer to $151, which frames the current discussion around upside expectations.
Strong ongoing adoption and utilization of iDose TR, a first-of-its-kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies, a substantial long-term opportunity given the aging population and rising prevalence of glaucoma, likely driving robust multi-year revenue and market expansion.
Curious what sits behind that valuation gap for Glaukos stock? The narrative leans heavily on aggressive revenue compounding, rising margins, and a rich future profit multiple. Want to see how those moving pieces are stitched together and what assumptions carry the most weight in that fair value story?
Result: Fair Value of $151.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Glaukos stock still faces meaningful risks, including heavier competition in glaucoma procedures and the chance that reimbursement or product uptake falls short of current expectations.
Find out about the key risks to this Glaukos narrative.
Another View: What Glaukos Multiples Are Signalling
While the SWS DCF model points to Glaukos stock trading at a large discount to estimated future cash flows, the picture from simple sales based multiples is tougher. At a P/S of 13.6x, Glaukos sits well above the US Medical Equipment industry at 2.6x and peer average at 5x, and even above a fair ratio of 7.7x that the market could move toward over time. That gap suggests investors are already paying a premium, so it is worth considering how comfortable you are with the growth and profitability story that needs to sit behind it.
To see how this premium lines up against the underlying numbers and potential risks, take a closer look at the valuation breakdown through our multiples lens, starting with See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Glaukos attracting both optimism and concern in this article, now is a good time to review the data yourself, decide where you stand, and then weigh up the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Glaukos stock?
Glaukos may have caught your eye, but you will miss plenty of other potential opportunities if you stop here, so put a broader watchlist to work today.
- Spot early stage opportunities with stronger balance sheets by scanning 23 elite penny stocks with strong financials before they hit the mainstream and get crowded.
- Zero in on quality businesses trading below what their fundamentals suggest by running the 44 high quality undervalued stocks and building a more price disciplined shortlist.
- Prioritise resilience and financial strength by filtering companies through the 67 resilient stocks with low risk scores so you are not caught off guard when conditions change.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com